Fiala

Peptide library › Heart & blood

Pegcetacoplan

Also known as Empaveli, Syfovre, Aspaveli

FDA-approved drugHeart & blood

Complement blocker used for the rare blood disease PNH (as an infusion under the skin) and for geographic atrophy in the eye (as an eye injection).

What people use it for

What Pegcetacoplan does in the body

A ring-shaped peptide attached to PEG that blocks complement C3, a central part of the immune system's complement cascade, which destroys red blood cells in PNH and damages the retina in geographic atrophy.

Strength of evidence

Strong: Phase 3 trials (PEGASUS in PNH; OAKS and DERBY in geographic atrophy).

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved as Empaveli (2021, PNH) and Syfovre (2023, eye). Empaveli carries a boxed warning for serious infections.

How it's taken

Route: Infusion under the skin twice weekly (Empaveli), or injection into the eye (Syfovre)

How long it lasts (half-life): About 8 days

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Pegcetacoplan privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Pegcetacoplan in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Heart & blood